22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › CYTEK BIOSCIENCES INC. › 2024-2025

CYTEK BIOSCIENCES INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and CYTEK BIOSCIENCES INC.’s Form 8-K, filed June 24, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 164Asset managers, any item
  • 893Fund votes
  • June 18, 2025Meeting date

Results at a glance

Meeting of June 18, 2025: 4 items on CYTEK BIOSCIENCES INC.’s Form 8-K, filed June 24, 2025: 2 approved · 1 passed (calculated) · 1 plurality election.

Dissent

Significant dissent: 1 director (58.8% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore CYTEK BIOSCIENCES INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by CYTEK BIOSCIENCES INC.

These tallies are CYTEK BIOSCIENCES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 24, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

CYTEK BIOSCIENCES INC. — official shareholder meeting results, meeting held June 18, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Richard Chin, MD 81,794,582---- 208,49921,866,390 99.7%Passed (calculated)—
Elect Director: Deborah Neff 33,819,367---- 48,183,71421,866,390 41%Plurality election—
2. Executive Compensation. On a non-binding, advisory basis, the compensation paid to the Company's named executive officers for the year ended December 31, 2024 76,368,8835,630,0574,141 --21,866,390 93%Approved—
3. Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 95,862,6127,657,004349,855 ---- 93%Approved—

Source: CYTEK BIOSCIENCES INC., Form 8-K, filed with the SEC on June 24, 2025 — read the filing on EDGAR.

How asset managers voted at the CYTEK BIOSCIENCES INC. 2024-2025 meeting

164 asset managers disclosed a vote on at least one CYTEK BIOSCIENCES INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Deborah Neff

Calculated outcomeDIRECTOR ELECTIONSPlurality election

Combines 5 wordings of this item as funds reported it.

41% Plurality election · of votes cast

FOR 41%WITHHELD
FOR: 33,819,367WITHHELD: 48,183,714
Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: To elect our two Class I director nominees, each to serve a three-year term, expiring at our 2028 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal: Deborah Neff

CYTEK BIOSCIENCES INC.’s own tally for this item (“Elect Director: Deborah Neff”): 33,819,367 for, 48,183,714 withheld, per its Form 8-K filed June 24, 2025 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.

Outcome: Plurality election — The company’s filing reports the vote counts but does not state the outcome; this is an election decided by plurality, so a nominee does not need a majority of the votes cast and no passed or failed outcome is calculated.
Support: 41% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 7,060,272 for, 13,721,242 withheld, 13,413,653 abstained.

FORABSTAINWITHHOLD
FOR: 7,060,272ABSTAIN: 13,413,653WITHHOLD: 13,721,242
Largest asset managers voting on “To elect our two Class I director nominees, each to serve a three-year term, expiring at our 2028 annual meeti” at CYTEK BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock00 12,475,2860Abstain
Vanguard9,7100 729,415,141Withhold
Fidelity2,606,1400 050,938For
Brown Capital Management Mutual Funds2,054,9700 00For
State Street3,2510 01,504,786Withhold
Charles Schwab970,2550 00For
Royce720,2790 00For
Goldman Sachs00 0490,680Withhold
Nationwide270,9480 0109,925Mixed
Equitable00 0343,929Withhold
TIAA301,8190 00For
Columbia Threadneedle00 0258,590Withhold
American Century00 0237,682Withhold
JPMorgan00 214,4450Abstain
QUANTITATIVE MASTER SERIES LLC00 209,7840Abstain
Jackson National00 205,5420Abstain
Lincoln Financial00 0171,673Withhold
AIG/SunAmerica00 0120,832Withhold
TIFF INVESTMENT PROGRAM00 115,8960Abstain
BNY Mellon00 0115,686Withhold
Prudential/PGIM96,2570 017,830Mixed
Principal00 0101,339Withhold
Brighthouse00 099,359Withhold
Empower00 088,987Withhold
Thrivent00 076,638Withhold

Showing the 25 largest of 59 asset managers. All 59 are in the interactive database (link above).

Elect Director: Richard Chin, MD

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 81,794,582WITHHELD: 208,499
Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: To elect our two Class I director nominees, each to serve a three-year term, expiring at our 2028 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal: Richard Chin, M.D.

CYTEK BIOSCIENCES INC.’s own tally for this item (“Elect Director: Richard Chin, MD”): 81,794,582 for, 208,499 withheld, per its Form 8-K filed June 24, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 34,191,253 for, 3,912 withheld, 0 abstained.

FOR
FOR: 34,191,253ABSTAIN: 0WITHHOLD: 3,912
Largest asset managers voting on “To elect our two Class I director nominees, each to serve a three-year term, expiring at our 2028 annual meeti” at CYTEK BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock12,475,2860 00For
Vanguard9,421,0090 03,912For
Fidelity2,657,0780 00For
Brown Capital Management Mutual Funds2,054,9700 00For
State Street1,508,0370 00For
Charles Schwab970,2550 00For
Royce720,2790 00For
Goldman Sachs490,6800 00For
Nationwide380,8730 00For
Equitable343,9290 00For
TIAA301,8190 00For
Columbia Threadneedle258,5900 00For
American Century237,6820 00For
JPMorgan214,4450 00For
QUANTITATIVE MASTER SERIES LLC209,7840 00For
Jackson National205,5420 00For
Lincoln Financial171,6730 00For
AIG/SunAmerica120,8320 00For
TIFF INVESTMENT PROGRAM115,8960 00For
BNY Mellon115,6860 00For
Prudential/PGIM114,0870 00For
Principal101,3390 00For
Brighthouse99,3590 00For
Empower88,9870 00For
Thrivent76,6380 00For

Showing the 25 largest of 59 asset managers. All 59 are in the interactive database (link above).

Executive Compensation. On a non-binding, advisory basis, the compensation paid to the Company's named executive…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

93% Approved · of votes cast

FOR 93%
FOR: 76,368,883AGAINST: 5,630,057

Prior year: 85.8% for (June 5, 2024 meeting) ▲ 7.3 pts

Details: description as filed, official tally, votes by 164 asset managers

Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS FOR THE YEAR ENDED DECEMBER 31, 2024, AS SET FORTH IN OUR PROXY STATEMENT.

CYTEK BIOSCIENCES INC.’s own tally for this item (“2. Executive Compensation. On a non-binding, advisory basis, the compensation paid to the Company's named executive officers for the year ended December 31, 2024”): 76,368,883 for, 5,630,057 against — passed, per its Form 8-K filed June 24, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “On a non-binding, advisory basis, the compensation paid to the Company's named executive officers for the year ended December 31, 2024 was approved based on the following results of voting:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 60 asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS FOR THE YEAR EN” at CYTEK BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock12,475,2860 00For
Vanguard9,421,0013,921 00For
Fidelity2,657,0780 00For
Brown Capital Management Mutual Funds02,054,970 00Against
State Street1,508,0370 00For
Charles Schwab970,2550 00For
Royce720,2790 00For
Goldman Sachs490,6800 00For
Nationwide116,364264,509 00Mixed
Equitable343,9290 00For
TIAA301,8190 00For
Columbia Threadneedle258,5900 00For
American Century237,6820 00For
JPMorgan214,4450 00For
QUANTITATIVE MASTER SERIES LLC209,7840 00For
Jackson National205,5420 00For
Lincoln Financial171,6730 00For
AIG/SunAmerica120,8320 00For
TIFF INVESTMENT PROGRAM115,8960 00For
BNY Mellon115,6860 00For
Prudential/PGIM114,0870 00For
Principal101,3390 00For
Brighthouse99,3590 00For
Empower88,9870 00For
Thrivent76,6380 00For

Fund voting reports, all 60 managers: 31,926,211 for, 2,324,428 against, 0 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 124 asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS FOR THE YEAR EN” at CYTEK BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
HHLR ADVISORS, LTD.6,657,0300 00For
BlackRock4,021,7250 00For
State Street3,794,1940 00For
BROWN CAPITAL MANAGEMENT LLC03,530,341 00Against
GEODE CAPITAL MANAGEMENT, LLC2,711,0390 00For
NEW YORK STATE COMMON RETIREMENT FUND2,088,3900 00For
Charles Schwab1,090,6070 00For
Northern Trust918,4170 00For
JACOBS LEVY EQUITY MANAGEMENT, INC751,7450 00For
MELLON INVESTMENTS Corp738,7030 00For
PRINCIPAL GLOBAL INVESTORS521,2330 00For
Impresa Management LLC517,7900 00For
Dimensional440,2180 00For
JPMorgan349,0040 00For
Nuveen304,9850 00For
GLOBEFLEX CAPITAL L P290,5110 00For
Vanguard276,2400 00For
PUBLIC SECTOR PENSION INVESTMENT BOARD250,7850 00For
AQR242,3530 00For
Citadel239,8720 00For
American Century237,6820 00For
STATE OF WISCONSIN INVESTMENT BOARD236,4180 00For
Fidelity201,3920 00For
Invesco191,2300 00For
Legal & General Investment Management America Inc0179,772 00Against

Institutional-manager reports, all 124 managers: 29,891,594 for, 4,102,672 against. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

93% Approved · of votes cast

FOR 93%
FOR: 95,862,612AGAINST: 7,657,004

Prior year: 97.6% for (June 5, 2024 meeting) ▼ 5.0 pts

Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

CYTEK BIOSCIENCES INC.’s own tally for this item (“3. Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December”): 95,862,612 for, 7,657,004 against — passed, per its Form 8-K filed June 24, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified based on the following results of voting:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 34,157,430 for, 37,736 against, 0 abstained.

FOR
FOR: 34,157,430AGAINST: 37,736ABSTAIN: 0
Largest asset managers voting on “TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE ” at CYTEK BIOSCIENCES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock12,475,2860 00For
Vanguard9,424,9157 00For
Fidelity2,657,0780 00For
Brown Capital Management Mutual Funds2,054,9700 00For
State Street1,507,459578 00For
Charles Schwab970,2550 00For
Royce720,2790 00For
Goldman Sachs490,6800 00For
Nationwide356,57324,300 00Mixed
Equitable343,9290 00For
TIAA301,8190 00For
Columbia Threadneedle258,5900 00For
American Century237,6820 00For
JPMorgan214,4450 00For
QUANTITATIVE MASTER SERIES LLC209,7840 00For
Jackson National205,5420 00For
Lincoln Financial171,6730 00For
AIG/SunAmerica120,8320 00For
TIFF INVESTMENT PROGRAM115,8960 00For
BNY Mellon115,6860 00For
Prudential/PGIM114,0870 00For
Principal101,3390 00For
Brighthouse99,3590 00For
Empower88,9870 00For
Thrivent76,6380 00For

Showing the 25 largest of 59 asset managers. All 59 are in the interactive database (link above).

Largest CYTEK BIOSCIENCES INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 126,659,196 shares outstanding at the time of that meeting.

Fund voting reports: top CYTEK BIOSCIENCES INC. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS…”, 2024-2025
#Asset manager % of shares outstanding
1BlackRock 9.85%
2Vanguard 7.44%
3Fidelity 2.10%
4Brown Capital Management Mutual Funds 1.62%
5State Street 1.19%
6Charles Schwab 0.77%
7Royce 0.57%
8Goldman Sachs 0.39%
9Nationwide 0.30%
10Equitable 0.27%
Institutional-manager reports: top CYTEK BIOSCIENCES INC. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS…”, 2024-2025
#Asset manager % of shares outstanding
1HHLR ADVISORS, LTD. 5.26%
2BlackRock 3.18%
3State Street 3.00%
4BROWN CAPITAL MANAGEMENT LLC 2.79%
5GEODE CAPITAL MANAGEMENT, LLC 2.14%
6NEW YORK STATE COMMON RETIREMENT FUND 1.65%
7Charles Schwab 0.86%
8Northern Trust 0.73%
9JACOBS LEVY EQUITY MANAGEMENT, INC 0.59%
10MELLON INVESTMENTS Corp 0.58%

Reported CYTEK BIOSCIENCES INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

CYTEK BIOSCIENCES INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Entities affiliated with BlackRock, Inc.18,482,795 14.59%Proxy statement (DEF 14A), proxy filed April 28, 2025
BlackRock18,069,282 14.27%Form 13F, quarter ended March 31, 2025
Entities affiliated with The Vanguard Group11,890,700 9.39%Proxy statement (DEF 14A), proxy filed April 28, 2025
Vanguard Group9,622,008 7.60%Form 13F, quarter ended March 31, 2025
Entities affiliated with Brown Capital Management, LLC9,493,474 7.50%Proxy statement (DEF 14A), proxy filed April 28, 2025
Millennium Management LLC7,872,900 6.22%Schedule 13G, filed May 18, 2026
Topline Capital Management, LLC6,780,847 5.35%Schedule 13G, filed November 17, 2025
Entities affiliated with Hillhouse Investment Management, Ltd.6,657,030 5.26%Proxy statement (DEF 14A), proxy filed April 28, 2025
Ming Yan, Ph.D.6,363,586 5.02%Proxy statement (DEF 14A), proxy filed April 28, 2025
Wenbin Jiang, Ph.D.6,094,266 4.81%Proxy statement (DEF 14A), proxy filed April 28, 2025

Percentages above are of 126,659,196 shares outstanding, as reported by CYTEK BIOSCIENCES INC. on its Form 10-Q dated April 30, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At CYTEK BIOSCIENCES INC.'s shareholder meeting held June 18, 2025, in the 2024-2025 proxy season, 164 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 893 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS… — CYTEK BIOSCIENCES INC.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CYTEK BIOSCIENCES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 24, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CYTEK BIOSCIENCES INC.’s 10-Q dated April 30, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

CYTEK BIOSCIENCES INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “CYTEK BIOSCIENCES (CTKB) 2025 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/cytek-biosciences-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.